TY - JOUR
T1 - Treatment of Glioma in the 21st Century
T2 - An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era
AU - Uhm, Joon H.
AU - Porter, Alyx B.
PY - 2017/6
Y1 - 2017/6
N2 - The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers’ understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.
AB - The past decade has brought about major changes in the way we classify and have begun to approach patients with high-grade glioma. As we trend toward personalized medicine, we are now able to utilize the molecular characteristics of each individual's tumor in order to tailor their treatment, particularly if the patient is elderly or has a poor performance status at baseline. We address the state of the practice as of 2016 in regard to chemotherapy, immunotherapy, and tumor-treating fields. The goal of this review is to enhance readers’ understanding of the nuances that are allowing clinicians to tailor the treatment of high-grade glioma more specifically.
UR - http://www.scopus.com/inward/record.url?scp=85026318645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026318645&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2017.01.010
DO - 10.1016/j.mayocp.2017.01.010
M3 - Review article
C2 - 28578786
AN - SCOPUS:85026318645
SN - 0025-6196
VL - 92
SP - 995
EP - 1004
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 6
ER -